Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents by Ciancio, Alessia et al.
1 
 
This article is protected by copyright. All rights reserved 
Research Article 
SIGNIFICANT IMPROVEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS 
WITH HCV INFECTION RESPONDING TO DIRECT-ACTING ANTIVIRAL AGENTS† 
Short title: HCV eradication with DAAs improves diabetes 
Alessia Ciancio1, Roberta Bosio2, Simona Bo3, Marianna Pellegrini3, Marco Sacco1, 
Edoardo Vogliotti1, Giulia Fassio2, Andrea Guido Franz Bianco Mauthe 
Degerfeld2, Monica Gallo2, Chiara Giordanino2, Lodovico Terzi di 
Bergamo1,Davide Ribaldone1, Elisabetta Bugianesi1, Antonina Smedile1, Mario 
Rizzetto1,  
Giorgio Maria Saracco1 
1Gastroenterology Unit, Department of MedicalSciences, AOU Città della Salute e della 
Scienza di Torino, University of Turin, Torino, Italy 
2Gastroenterology Unit, San Luigi Hospital, University of Turin,Torino,  Italy 
3Department of MedicalSciences, AOU Città della Salute e della Scienza di Torino, 
University of Turin, Torino, Italy 
Corresponding author: 
Giorgio Maria Saracco, MD, Gastro-hepatology Unit, Department of Medical Sciences,  
AOU Città della Salute e della Scienza di Torino, Corso Bramante 8810126 Torino, 
Italy.  
Tel.: +39-011-6336397.FAX: +39-011-6335927.  
E-mail: giorgiomaria.saracco@unito.it 
Conflicts of interest: none declared. 
Source of funding: none declared. 
 
†This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
[10.1002/jmv.24954] 
Received 14 August 2017; Revised 19 September 2017; Accepted 19 September 2017 
Journal of Medical Virology 
This article is protected by copyright. All rights reserved 
DOI 10.1002/jmv.24954 
2 
 
This article is protected by copyright. All rights reserved 
ABSTRACT 
AIM:Many studies showed insulin resistance amelioration in HCV-patients achieving 
Sustained Virologic Response (SVR) but results on glycaemic control in diabetic 
patients are unclear. 
This study aimed to assess fasting glucose (FG) and glycated haemoglobin (HbA1c) 
values before and after therapy with direct-acting antivirals (DAAs) in HCV-patients 
with type 2 diabetes mellitus (T2DM).  
METHODS:Of the 122 consecutively recruited patients with chronic hepatitis C and 
T2DM, 110 patients were treated with DAAs and 12 remained untreated.  Clinical, 
biochemical, virological and metabolic features were collected both at baseline and at 
12 weeks after the end of therapy (EOT) or after a comparable period of time in 
untreated patients.  
RESULTS:101 patients obtained a SVR (Group 1), while nine were relapsers; Group 2 
(21 patients) was composed by the 9 relapsers and the 12 untreated patients. A 
significant reduction of mean FG (134.3±41.32 mg/dL vs 152.4± 56.40 mg/dL, p= 
0.002) and HbA1c values (46.51±16.15 mmol/mol vs 52.15±15.43 mmol/mol,p< 0.001) 
was found in Group 1 but not in Group 2 (140.6±47.87 mg/dL vs 145.31±30.18 mg/dL, 
p=0.707, and 55.31±20.58 mmol/mol vs 53.38±9.49 mmol/mol, p= 0.780). 
In Group 1, 20.7% of patients could reduce or suspend their antidiabetic therapy 
compared to none in Group 2 (p= 0.03), despite the significant weight increase observed 
in Group 1.  
CONCLUSIONS: SVR induced a significant amelioration of glycaemic control in 
diabetic HCV-patients, despite a significant weight increase; larger prospective studies 
are needed to verify whether these results are maintained over the longterm. This article 
is protected by copyright. All rights reserved 
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List of abbreviations in the order of appearance: 
HCV, hepatitis C virus; T2DM, type 2 diabetes mellitus; CHC, chronic hepatitis C; 
HCC, hepatocellular carcinoma; IR, insulin resistance; IFN, interferon; SVR, sustained 
virologic response; DAAs, direct-acting antivirals; FG, fasting glucose; HbA1c, 
glycated haemoglobin; OLT, orthotopic liver transplant; INHS, Italian national health 
system; EASL; European Association for the Study of the Liver; AH, arterial 
hypertension; MS, metabolic syndrome; BMI, body mass index; WC, waist 
circumference; HC, hip circumference; WHR, Waist-to-Hip Ratio; IL28B, Interleukin 
28B; AST, aspartate aminotransferase; ALT, alanine aminotransferase; APH, alkaline 
phosphatase; GGT, gamma glutamyltranspeptidase; TE, transient elastography; US, 
ultrasound scan; KPa, kilopascal; IQR, interquartile range; CAD, coronary artery 
disease; ECG, electrocardiograms; OR, odds ratio;CI, confidence interval; RBV, 
ribavirin; IRS, insulin receptors; SOC, suppressor of cytokines; UKPDS, UK 
Prospective Diabetes Study.
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INTRODUCTION 
A burden of data suggests that Hepatitis C Virus (HCV) can impair insulin signalling 
and boost the onset of type 2 diabetes mellitus (T2DM) beyond and in addition to the 
histological severity of the associated liver disease1-3. The increased metabolic risk 
associated with HCV infection is supported either by cross-sectional and longitudinal 
studies: the prevalence of T2DM in chronic hepatitis C (CHC) ranges between 19%-
33%4,5 and its incidence is increased in patients with CHC after liver transplantation6,7.  
In turn, T2DM in CHC seems not only to accelerate the progression of liver disease8-10 
but also to greatly increase the risk of hepatocellular carcinoma (HCC)11-13, even in 
patients without cirrhosis and after the eradication of HCV infection14.  For this reason, 
reducing the incidence of T2DM and improving the glycaemic control of diabetic 
patients with CHC are of paramount importance.  If HCV is directly involved in the 
development of insulin resistance (IR) and T2DM, its clearance should result in a 
parallel decrease in the risk of DM incidence. Accordingly, a successful eradication of 
HCV could improve IR, glycaemic control and clinical outcomes in patients with 
established T2DM. 
In the era of interferon (IFN)-based therapy, this hypothesis was  very difficult to be 
tested due to the very low Sustained Virologic Response (SVR) rates associated to IR 
and T2DM15-18 for the negative impact of metabolic abnormalities on therapeutic 
efficacy.  Nevertheless, some clinical trials19,20 concurred to demonstrate that SVR was 
associated with improved IR. On the contrary, baseline IR and T2DM do not seem to 
affect the outcomes of Direct-Acting Antivirals (DAAs)-based therapy21-23  and the high 
therapeutic efficacy of novel antivirals will ensure viral eradication in a large number of 
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diabetic patients.  Recent preliminary reports suggest that DAA agents are associated 
with improvement of fasting glucose (FG) and glycated haemoglobin (HbA1c) values 
during24 and after therapy25-27 in diabetic patients.  Although the results of these studies 
suggest benefits of DAAs on glycemic control, their anecdotal format and/or 
retrospective design make questionable a generalization of their conclusions. 
In order to assess whether SVR has a clinical impact on glycaemic control, we 
prospectively recruited HCV-positive patients with T2DM receiving DAAs and 
evaluated their FG andHbA1c levels at baseline and 12 weeks post-treatment; the 
influence of SVR on antihyperglycaemic medication needs was also assessed.  
Potentially confounding factors affecting the results (i.e. weight variation) were 
considered.  
 
 
METHODS 
All the consecutive patients with CHC and T2DM referred to two academic centers of 
North-Western Italy (Gastrohepatologic Clinic of Molinette Hospital, Turin, Italy and 
Gastroenterology Division of San Luigi Hospital, Orbassano, Italy) between January 
and December 2015 were considered. Patients were included into the present study if 
they fulfilled the following criteria at baseline: age > 18 years; positive results for HCV-
RNA by polymerase chain reaction (PCR); CHC at transient elastography; T2DM. 
Exclusion criteria were: lack of written informed consent, patients in waiting list for 
orthotopic liver transplant (OLT), post-OLT patients,  Child-Pugh C patients, active 
alcohol intake, presence of ascites, presence of other concomitant liver diseases such as 
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haemochromatosis, Wilson's disease, drug-related liver disease, autoimmune hepatitis, 
HbsAg carriership, HIV infection, primary biliary cirrhosis, 1-antitrypsin deficiency. 
In 2015, due to Italian National Health System (INHS) rules, only patients with 
advanced liver fibrosis (F3-F4 according to METAVIR Score28) or with severe 
extrahepatic diseases linked to C virus could be reimbursed for treatment with DAAs; 
for this reason, a significant minority of diabetic patients with CHC remained untreated: 
each of them was asked to participate into the study as controls. Out of remaining 
treatable patients, three refused to be treated but accepted to serve as controls. 
Overall, 156 diabetic patients were screened and 122 (78.2%) were included into the 
study. Patients' flow is reported on Figure 1. One hundred and ten patients were treated 
with DAAs for 12-24 weeks (Table 1) according to the European Association for the 
Study of the Liver (EASL) guidelines29, 101 (91.8%) showed a SVR (HCV-RNA 
clearance 12 weeks after the end of therapy); 9 of 110 (8.2%) demonstrated a viremic 
relapse 4 weeks after the end of treatment and remained HCV-RNA positive at week 12.  
Twelve patients were untreated and served as controls for a comparable period of time.  
Overall, 101 patients who achieved SVR were allocated to Group 1 and 21 who did not 
obtain SVR or were untreated were attributed to Group 2. 
At baseline, a complete medical history and physical examination was undertaken and 
the following data were obtained: age, gender, smoking status,family history for T2DM, 
duration of T2DM, type of antidiabetic medication,presence of macro/ microangiopathic 
complications, arterial hypertension (AH), relevant co-morbidities and the metabolic 
syndrome (MS),body mass index (BMI), waist circumference (WC), hip circumference 
(HC),waist/hip ratio (WHR), HCV genotype, Interleukin-28Brs12979860 (IL-28B) 
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status.  Serum samples were drawn after an overnight (12-h) fasting period in order to 
assess the viral load (AmpliPrep®/COBAS Taqman® HCV test, Roche Diagnostics, 
Basel, Switzerland), complete blood count, routine liver biochemistry (alanine 
aminotransferase [AST], aspartate aminotransferase [AST] levels, total bilirubin, 
albumin, alkaline phosphatase [APH], gamma glutamyltranspeptidase [GGT]),FG and 
HbA1c (high-performance liquid chromatography, HPLC G8 Analyzer,  Thoso, USA, 
normal values: 20-38 mmol/mol) values.  Components of the MS, including central 
obesity, hypertriglyceridemia, hypertension and low HDL cholesterol, were recorded. 
The severity of liver fibrosis was determined within 3 months from treatment by 
transient elastography (TE) and patients were stratified according to METAVIR Scale28. 
An abdominal ultrasound (US) was performed in each patient at baseline and at the end 
of the study (EOS).  Baseline and EOS aliquoted plasma samples were stored at -80° C 
until assayed.  Plasma insulin concentrations were assessed in patients who had never 
received antihyperglycemic agents by a double antibody radioimmunoassay (Diagnostic 
Products Corporation, Los Angeles, CA; interassay coefficient of variation <13%).  IR 
was calculated on the basis of fasting glucose and insulin levels according to the 
homeostatic assessment of insulin resistance (HOMA-IR) method30. 
After 12 weeks from the end of therapy (or after a comparable period of time in 
untreated patients), the anthropometric features and the abovementioned serum 
measurements were re-assessed in each patient.  
The study was performed in accordance with the principles of the Declaration of 
Helsinki and approved by the local ethics committee (Comitato Etico Interaziendale 
Città della Salute e della Scienza di Torino, Turin, Italy; Comitato Etico AOU S. Luigi 
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Gonzaga di Orbassano, Orbassano, Italy); written informed consent was obtained from 
all patients. 
 
Definitions 
Smokers were defined as persons smoking more than one cigarette per day or known to 
have smoked within three years before the study recruitment.  BMI was calculated as 
weight in kilograms divided by the square of the height in meters with the subjects 
wearing light clothing but no shoes. WC was measured at the midpoint between the 
lower border of the rib cage and the iliac crest.  HC was measured at the widest point 
between hip and buttocks. WHR was defined as WC (cm) divided by HC (cm). Blood 
pressure was reported as the average of the last three determinations.  Hypertension was 
defined as a systolic or diastolic blood pressure of 130/80 mmHg or higher or a current 
anti-hypertensive treatment31.   
According to the criteria recommended by the Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus, diabetes was defined as fasting plasma glucose ≥ 
126 mg/dl (7 mmol/l) in two separate measurements32. 
Diagnosis of metabolic syndrome was made according to the criteria suggested by the 
International Diabetes Federation33.   
 
Liver stiffness evaluation 
Liver stiffness measurements were performed within 3 months from the start of the 
study using TE (FibroScan®, Echosens, Paris, France) according to current EASL 
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guidelines34; the validated probe according to BMI was used (M probe if BMI<28 
kg/m2, XL probe if BMI >28 kg/m2).  Results were recorded in kilopascal (KPa); 
patients were fasting for a minimum of 6 hours prior to TE.  Values for each patient 
were calculated as median of a minimum of 10 consecutive measurements and exams 
with an interquartile range (IQR) divided by mean value (IQR/M) of >30% or a success 
rate of 60% were excluded as recommended by current guidelines.  Patients were 
subsequently divided into 4 groups (F0-F1, F2, F3, F4) according to the METAVIR 
Scale28.  Patients with cirrhosis underwent upper endoscopy within 3 months from the 
study inclusion in order to verify the presence of oesophageal/gastric varices.  
 
Diabetic complications 
Coronary artery disease (CAD) was assessed by a conventional 12-lead resting 
electrocardiograms (ECG) interpreted by two trained cardiologists and/or presence of 
documented events, recorded by a physician (i.e. angina, previous myocardial 
infarction, coronary artery bypass graft or other invasive procedures to treat CAD); 
peripheral artery disease was defined when conditions such as ischaemic foot ulcers, 
gangrene, amputation, vascular surgery, transient ischaemic attacks, strokes, 
intermittent claudication, absent foot pulses, abnormal brachial and posterior tibial 
blood pressure using Doppler techniques were reported.  Retinopathy was diagnosed by 
ophthalmoscopy examination performed by an ophthalmologist experienced in diabetic 
retinopathy.  Nephropathy was established by the presence of an albumin excretion rate 
higher than 20 µg/min at least in two of three urine collections.  Distal symmetric 
polyneuropathy was diagnosed by the presence of neuropathic symptoms, an abnormal 
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vibration perception threshold, the absence of ≥2 ankle or knee reflexes and/or an 
abnormal electromyographic test.  Autonomic neuropathy was diagnosed by a loss of 
heart rate variability or postural hypotension. 
 
Statistical analysis 
Patients’ characteristics at baseline and at the end of follow-up were compared between 
groups using the Student t test for continuous variables and the chi-square (or Fisher's 
Exact Test), when expected cell frequencies were less than 5 for categorical variables. 
In particular, weight, waist and hips circumference and biochemical changes were 
analyzed by paired t-test for the interval between baseline to 12 weeks after the end of 
therapy (up to 252 days from baseline).  Association between predictor variables and 
glycaemic control improvement were determined by Odds Ratio (OR) and 95% 
confidence interval (CI) calculated using Cox proportional hazards regression.  
Variables with p< 0.1 in the univariate model were included in the multivariate model. 
 
 
RESULTS 
All patients included in the study protocol were Caucasian; Table 2 summarizes 
baseline demographic, anthropometric and clinical characteristics of patients who 
achieved SVR (Group 1) and those who did not or who had not been treated (Group 2).  
Baseline liver-related and diabetes-related features are reported in Table 3.  Age, 
gender, BMI, abdominal circumferences, hypertension and metabolic syndrome rates, 
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comorbidities, viral genotypes and viremia, IL-28B status, GGT levels were not 
significantly different between the two groups.  Not surprisingly, Group 2 patients had 
significantly lower liver stiffness (p= 0.024) as 57% of them could not have access to 
therapy due to fibrosis lower than F3, according to current INHS rules.  No significant 
differences regarding Child-Pugh status, previous HCC and presence of gastro-
oesophageal varices were found between patients with cirrhosis from both groups. 
Values of FG and HbA1c levels, antidiabetic medications and prevalence of 
macro/microangiopathic complications were comparable between the two groups (Table 
3). 
At the end of the study, Group 1 patients showed a statistically significant decrement of 
FG (134.3±41.32 mg/dL, p= 0.002) and HbA1c (46.51±16.15 mmol/mol, p < 0.001) 
levels; among Group 2 patients, no significant variation in FG (140.6±47.87 mg/dL, p = 
0.707) and HbA1c (55.31±20.58 mmol/mol, p = 0.780) values was found.  Liver 
function and T2DM parameters of both groups before and at the end of the study are 
reported in Table 4.  
To verify whether ribavirin (RBV) might have influenced post-treatment HbA1c values 
through its hemolytic effect, we analyzed treated patients who achieved SVR according 
to the use of the medication: a significant decrease of HbA1c levels was observed both 
in 74 patients receiving RBV   (p= 0.024) and in 27 patients not given RBV (p= 0.007). 
Finally, in order to individuate predictive factors clinically relevant for glycaemic 
amelioration (defined as a ≥20% decrease of HbA1c levels), we used a Cox proportional 
hazard risk model (Table 5).  Based on a multivariable regression analysis, SVR was the 
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only independent predictive factor associated with the improvement of glycaemic 
control (OR= 49.75, 95% CI 2.197-112.67, p= 0.014). 
 
Weight and antidiabetic treatment changes 
Among Group 1 patients, the mean weight change from baseline to SVR was + 
2.61±6.13 kg (p= 0.023); no significant weight variation was observed in Group 2 
patients (+ 0.26±1.34 kg, p= 0.56).  Baseline to SVR, 63 of 101 (62.3%) sustained 
responders gained weight (mean gain 4.13±3.12 kg), 9 (8.9%) lost weight (mean loss 
3.2±2.43 kg) and 29 (28.8%) maintained a stable weight compared to 6 (28.6%, mean 
gain 2.34±1.86 kg), 4 (19%, mean loss 1.85±1.34kg) and 11 (52.4%) respectively 
ofGroup 2 patients (p= 0.02).  Group 1 patients with or without significant improvement 
of glycaemic control (≥20% decrease of HbA1c levels) were then stratified according to 
the weight variation: 18 (28.5%) out of 63 patients showing weight increase achieved a 
significant amelioration of HbA1c values compared to 16 (42.1%, p= 0.074) of 38 
patients demonstrating either weight decrease or stable weight. 
Antihyperglycaemic agents tapering off because of improved glycaemic control was 
exclusively observed in Group 1, in 21 (20.7%) of the 101 patients who achieved SVR 
(p= 0.03); in particular, 8 of 19 (42.1%) patients treated by oral hypoglicaemic drugs 
reduced or suspended their therapy and 13 of 46 (28.2%) patients on insulin therapy 
decreased the dosage or withdrew the treatment, despite their mean weight gain of 
2.85±4.33 kg. 
13 
 
This article is protected by copyright. All rights reserved 
Nine (8.9%) patients had to escalate their antihyperglicaemic medications compared to 
1 (4.8%) of Group 2 (p= 0.34); this subset of patients showed a mean weight increase of 
5.8±3.12 kg. 
 
 
DISCUSSION 
In our study, clearance of HCV induced a significant improvement in glycaemic control 
among 101 diabetic patients, as demonstrated by the reduction of FG and HbA1c levels 
12 weeks after the end of treatment with DAAs.  This result was obtained despite the 
weight gain observed in more than 60% of cured patients, suggesting that improved 
glycaemic control was not due to lifestyle change.  The weight increase found in our 
patients was surprising but not unexpected as it was already described by Azad and 
coll.35 who reported a significantly higher mean weight gain in diabetic patients 
compared to non-diabetics treated with sofosbuvir + ledipasvir (+5.8±7.2 pounds versus 
1.9±7.8 pounds, p= 0.03).  The reason for the weight increase observed among diabetic 
patients with SVR is still unexplained; we can speculate that the awareness of being 
definetively cured for HCV might have induced a less stringent nutritional compliance 
in the responders.  Our multivariate analysis did not reveal confounders in the 
association between SVR and glycaemic control improvement, providing indirect 
support for a causal role of HCV in the induction of T2DM.  The way whereby HCV 
induces T2DM is IR3; HCV was shown to impair the hepatocyte insulin signalling 
pathway by several ways36, including the stimulus to the production of tumour necrosis 
factor-α, the serine phosphorylation of the insulin receptors (IRS), the over-expression 
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of the suppressor of cytokines (SOC-3)37,38 and the induction of SOC-739. The 
mechanism through which DAAs therapy ± RBV ameliorates IR has not been fully 
established but it is most likely mediated via viral clearance, rather than a direct 
pharmacological effect.  To date, many reports15,19,20,40 showed that HCV clearance is 
associated with a significant improvement of IR but our study has demonstrated that this 
amelioration translates into a definite clinical benefit for diabetic patients.  In fact, the 
improved glycaemic control had a relevant impact on antihyperglycemic medication 
needs in patients who achieved SVR; if we exclude patients on diet only, more than 
30% of diabetics decreased the dosage or withdrew the treatment.  On the other hand, 9 
(8.9%) patients showing a particularly relevant weight gain (+ 5.8±3.12 kg) had to 
escalate their anti-diabetic therapy despite the viral clearance; for this reason, the 
eradication of HCV in diabetic patients should not preclude proper counselling on diet 
and physical activity continuation. 
If confirmed over the longterm, improvement of glycaemic control might add other 
benefits to diabetics with advanced liver disease who achieved SVR.  First, good 
glycaemic control prevents the onset and progression of acute and long-term diabetes-
related complications and, conversely, poor metabolic control could enhance or 
accelerate diabetes-related events. This is what usually occurs in ordinary HCV-
negative diabetic patients where long-term tight glycemic control is difficult to achieve, 
as demonstrated in the UK Prospective Diabetes Study (UKPDS), showing an 
inexorable decline in glucose control over time41. 
It is reasonable to hypothesize that a successful eradication of HCV would improve 
clinical outcomes in patients with T2DM as reported by a recent study42 showing that in 
diabetic patients with CHC treated with IFN/RBV and followed up for more than 7 
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years, none of those who obtained SVR developed retinopathy and/or neuropathic 
symptoms. 
Secondly, T2DM remains a strong risk factor for HCC development in cirrhotics after 
SVR has been obtained43,44  but a good glycaemic control seems to reduce the incidence 
of HCC45,46. Third, pre-OLT diabetes is associated with increased incidence of post-
OLT mortality47; a recent study48 showed that good glycaemic control pre-operatively 
may protect against the harmful effect of T2DM on infection and is associated with a 
reduced risk of readmission to intensive care unit and a reduced length of stay in 
hospital.  
Our findings have some limitations: although statistically significant, our results are 
issued from a study including a relatively small and selected population of patients with 
HCV infection and mild T2DM and need to be confirmed by larger studies, including 
patients with severe T2DM of long duration.  Moreover, before drawing definite 
conclusions, our study needs a longer follow up period in order to assess whether the 
results obtained by SVR regarding glycaemic control are maintained over the longterm 
and – more important – if this improvement will have an impact on T2DM outcome.  It 
is conceivable that among CHC patients, T2DM natural history may be influenced not 
only by viral clearance but also by genetic and lifestyle-related aspects, such as dietary 
habits, physical activity and adherence to therapy.  We still need to assess if viral 
eradication is “per se” a protection from T2DM complications or whether the 
abovementioned factors play anyway a pivotal role in the outcome of the disease. 
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Finally, the impact of baseline liver steatosis on post-SVR glycemic control was not 
studied and we were not able to report details regarding oral hypoglycemic agents. 
In conclusion, a significant improvement of glycaemic control was observed in diabetic 
patients with CHC who obtained SVR with a clinically meaningful de-escalation of 
antihyperglycaemic therapy; these findings raise the question as to whether the HCV 
eradication may also impacts the future morbidity and mortality due to T2DM.  For this 
reason, close T2DM follow up post-HCV treatment is warrantedand large prospective 
studies are needed to validate these results. 
 
ACKNOWLEDGEMENTS 
No specific funding was obtained for this study. 
 
 
 
17 
 
This article is protected by copyright. All rights reserved 
 
REFERENCES 
1. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a 
systematic review and meta-analysis.  J Hepatol 2008; 49: 831-844 
2. Naing C, Mak JW, Ahmed SI, Maung M.  Relatioship between hepatitis C virus 
infection and type 2 diabetes mellitus: a meta-analysis.  World J Gastroenterol 
2012  18: 1642-51 
3. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes 
mellitus, and cardiovascular diseases. J Hepatol 2014; 61: S69-S78 
4. Mason AL, Lau JY, Hoang N et al.  Association of diabetes mellitus and chronic 
hepatitis C virus infection.  Hepatology 1999  29: 328-333 
5. Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. High 
prevalence of glucose abnormalities in patients with hepatitis C virus infection: a 
multivariate analysis considering the liver injury. Diabetes Care2004; 27: 1171-
1175 
6. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH.  Higher 
incidence of diabetes in liver transplant recipients with hepatitis C.  J 
ClinGastroenterol 1998  26: 30-33 
7. Delgado-Borrego A, Liu YS, Jordan SH et al.  Prospective study of liver 
transplant recipients with HCV infection: evidence for a causal relationship 
between HCV and insulin resistance.  Liver Transpl 2008 14: 193-201 
8. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic 
hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 
1695-1704 
18 
 
This article is protected by copyright. All rights reserved 
9. Bugianesi E, Marchesini G, Gentilcore E et al. Fibrosis in genotype 3 chronic 
hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and 
hepatic steatosis. Hepatology 2006; 44: 1648-1655 
10. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin 
resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 
723-731 
11. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular 
carcinoma: a cohort study in high prevalence area of hepatitis virus infection. 
Hepatology 2006; 43: 1295-1302 
12. Veldt BJ, Chen W, Heathcote EJ et al. Increased risk of hepatocellular 
carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. 
Hepatology 2008; 47: 1856-1862 
13. Giordanino C, Ceretto S, Bo S et al. Type 2 diabetes mellitus and chronic 
hepatitis C: which is worse? Results of a long-term retrospective cohort study. 
Dig Liver Dis  2012; 44: 406-412 
14. Hung CH, Lee CM, Wang JH et al.  Impact of diabetes mellitus on incidence of 
hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-
based antiviral therapy.  Int J Cancer 2011; 128: 2344-2352 
15. Romero-Gómez M, Del Mar Viloria M, Andrade RJet al.Insulin resistance 
impairs sustained response rate to peginterferon plus ribavirin in chronic 
hepatitis C patients. Gastroenterology 2005; 128: 636-641 
16. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in 
liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J 
Gastroenterol 2005; 100: 1509-1515 
19 
 
This article is protected by copyright. All rights reserved 
17. Persico M, Capasso M, Persico E et al. Suppressor of cytokine signaling3 
(SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin 
resistance and response to antiviral therapy. Hepatology 2007; 46: 1009-1015 
18. Poustchi H, Negro F, Hui J et al. Insulin resistance and response to therapy in 
patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 
2008; 48: 28-34 
19. Delgado-Borrego A, Jordan SH, Negre B et al.  Reduction of 
insulinresistancewitheffectiveclearance of Hepatitis C infection: resultsfromthe 
HALT-C trial.  ClinGastroenterol Hepatol 2010  8: 458-462 
20. Aghemo A, Prati GM, Rumi MG et al. A sustained virological response 
preventsdevelopment of insulinresistance in chronic hepatitis C patients. 
Hepatology 2012; 56: 1681-1687 
21. YounossiZ, Negro F, Serfaty L et al.  Homeostasis model assessment of insulin 
resistance does not seem to predict response to telaprevir in chronic hepatitis C 
in the REALIZE trial.  Hepatology 2013  58: 1897-1906 
22. Serfaty L, Forns X, Goeser T et al.  Insulin resistance and response to telaprevir 
plus peginterferon alpha and ribavirin in treatment-naïve patients infected with 
HCV genotype 1.  Gut 2012  61: 1473-1480 
23. Willemse SB, Baak LC, Kuiken SD et al.  Sofosbuvir plus simeprevir for the 
treatment of HCV genotype 4 patients with advanced fibrosis or compensated 
cirrhosis is highly efficacious in real life.  J Viral Hepat 2016  23:950-954 
24. Pavone P, Tieghi T, D’EttorreGet al.  Rapid decline of fasting glucose in HCV 
diabetic patients treated with direct-acting antiviral agents.  ClinMicrobiol Infect 
2016  22: 462.e1-462.e3 
20 
 
This article is protected by copyright. All rights reserved 
25. Pashun RA. Shen NT, Jesudian A.  Markedly improved glycemic control in 
poorly controlled type 2 diabetes following Direct Acting Antiviral treatment of 
genotype 1 Hepatitis C.  Case Rep Hepatol 2016  
http://dx.doi.org/10.1155/2016/7807921 
26. Fabrizio C, Procopio A, Scudeller L et al.  HCV and diabetes: towards a 
“Sustained” glycaemic improvement after treatment with DAAs ?ClinMicrobiol 
Infect 2016 doi: 10.1016/j.cmi.2016.09.021 
27. LeClerc SB, Falck-Ytter Y, Falck-Ytter C, Pascuzzi K, Burant C, Rife K.  Viral 
response to hepatitis C direct-antiviral significantly improves diabetes control.  
Hepatology 2016 64 (suppl. 1): 488A  
28. METAVIR Cooperative Study Group.  Intraobserver and interobserver 
variations in liver biopsy interpretation in patients with chronic hepatitis C.  
Hepatology 1994  20: 15-20 
29. Pawlotsky JM, Aghemo A, Back D et al.  EASL recommendations on treatment 
of Hepatitis C 2015.  J Hepatol 2015  63: 199-236 
30. Wallace TM, Levy JC, Matthews DR.  Use and abuse of HOMA modeling.  
Diabetes Care 2004  27: 1487-1495 
31. ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 
Practice Guidelines for the management of arterial hypertension of the European 
Society of Hypertension (ESH) and the European Society of Cardiology (ESC): 
ESH/ESC Task Force for the Management of Arterial Hypertension.  J 
Hypertens 2013  31: 1925-1938 
32. American Diabetes Association.  Diagnosis and classification of diabetes 
mellitus.  Diabetes care 2011  34 (suppl. 1): 62-69 
21 
 
This article is protected by copyright. All rights reserved 
33. George K, Alberti MM, Zimmet P, Shaw J.  The metabolic syndrome – a new 
worldwide definition.  IDF Epidemiology Task Force Consensus Group.  Lancet 
2005  366: 1059-1062 
34. European Association for the Study of the Liver, AsociacionLatinoamericana 
para el Studio del H., EASL-ALEH. Clinical Practice Guidelines: Non-invasive 
tests for evaluation of liver disease severity and prognosis.  J Hepatol 2015  63: 
237-264 
35. Azad A, Bichoupan K, Chekuri S, Schiano T, Branch AD.  Diabetes is a risk 
factor for weight gain among patients cured of HCV with Sofosbuvir/ledipasvir.  
Hepatology 2016  64 (suppl. 1): 377A 
36. Kaddai V, Negro F. Current understanding of insulin resistance in hepatitis C. 
Expert Rev Gastroenterol Hepatol 2011; 5: 503-516 
37. Kawaguchi T, Yoshida T, Harada M et al.  Hepatitis C virus down-regulates 
insulin receptor substrates 1 and 2 through up-regulation of suppressor of 
cytokine signalling 3.  Am J Pathol 2004  165: 1499-1508 
38. Persico M, Russo R, Persico E et al.  SOCS3 and IRS-1 gene expression differs 
between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells.  
ClinChem Lab Med 2009  47: 1217-1225 
39. Pazienza V, Vinciguerra M, Andriulli A, Mangia A.  Hepatitis C virus core 
protein genotype 3° increases SOCS-7 expression through PPAR-γ in Huh-7 
cells.  J Gen Virol 2010  91: 1678-1686 
40. Kawaguchi Y, Mizuta T, Oza N et al. Eradication of hepatitis C virus by 
interferon improves whole-body insulin resistance and hyperinsulinemia in 
patients with chronic hepatitis C.  Liver Int 2009; 29: 871-877 
22 
 
This article is protected by copyright. All rights reserved 
41. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose 
control with sulphonylureas or insulin compared with conventional treatment 
and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 
1998; 352: 837-53.  
42. Coppo C, Bonfanti D, Bo S et al.  Risk of microangiopathy in type 2 diabetes 
mellitus patients with or without chronic hepatitis C.  Results of a retrospective 
long-term controlled cohort study.  Dig Liv Dis 2015  47: 405-410 
43. Hedenstierna M, Nangarhari A, Weiland O, Aleman S.  Diabetes and cirrhosis 
are risk factors for hepatocellular carcinoma after successful treatment of 
chronic hepatitis C.  Clin Infect Dis 2016  63: 723-729 
44. Van der Meer AJ, Feld JJ, Hofer H et al.  Risk of cirrhosis-related complications 
in patients with advanced fibrosis following hepatitis C virus eradication.  J 
Hepatol 2016  http://dx.doi.org/10.1016/j.jhep.2016.10.017 
45. Donadon V, Balbi M, Valent F, Avogaro A.  Glycated hemoglobin and 
antidiabetic strategies as risk factors for hepatocellular carcinoma.  World J 
Gastroenterol 2010  16: 3025-3032 
46. Arase Y, Kobayashi M, Suzuki F et al.  Effect of type 2 diabetes on risk for 
malignancies includes hepatocellular carcinoma in chronic hepatitis C.  
Hepatology 2013  57: 964-973 
47. Aguilar M, Liu B, Holt EW, Bhuket T, Wong RJ.  Impact of obesity and 
diabetes on waitlist survival, probability of liver transplantation and post-
transplant survival among chronic hepatitis C virus patients.  Liver Int 2016  36: 
1167-1175 
23 
 
This article is protected by copyright. All rights reserved 
48. Boughton C, Mustafa O, Suddle A et al.  Good glycaemic control pre-
operatively protects against adverse outcomes associated with diabetes in liver 
transplant recipients.  Hepatology 2016  64 (suppl. 1): 493A  
24 
 
This article is protected by copyright. All rights reserved 
FIGURE LEGENDS 
Figure 1.  Flow of the recruited patients. 
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TABLES 
Table 1. Antiviral treatment of diabetic patients. 
 
 
Patients, n (%) SVR, n (%) 
Sofosbuvir + ribavirin 13 (11.8%) 12 (92.3%) 
Sofosbuvir + Daclatasvir 
with or without ribavirin 
11 (10%) 11 (100%) 
Sofosbuvir + Ledipasvir with 
or without ribavirin 
46 (41.8%) 44 (95.6%) 
Sofosbuvir + Simeprevir with 
or without ribavirin 
22 (20%) 18 (81.8%) 
Ombitasvir-Paritaprevir-
Ritonavir with or without 
ribavirin 
6 (5.5%) 5 (83.3%) 
Ombitasvir-Paritaprevir-
Ritonavir + Dasabuvir with 
or without ribavirin 
12 (10.9%) 11 (91.7%) 
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Table 2. Baseline demographic, anthropometric and clinical features of 
the patients. 
 
† mean ± SD 
 
Group 1 
(101 pts) 
Group 2 
(21 pts) 
p 
Male, n (%) 71 (70.3%) 14 (66.7%) 0.945 
Age† (years) 61.39 ± 10.92 65.06± 13.12 0.276 
Weight† (kg) 75.29 ± 13.70 76.62 ± 19.33 0.771 
Height† (cm) 169 ± 8 168 ± 12 0.722 
BMI† (kg/m2) 26.58 ± 4.70 27.63 ± 4.81 0.401 
Smokers, n (%) 22 (21.8%) 5 (23.8%) 0.411 
Waist Circumference†(cm) 107.94 ±12.65 101.00 ±8.97 0.067 
Hip Circumference†(cm) 100.84 ±13.09 103.75 ±13.49 0.509 
Waist/Hip ratio 1.07 0.97 0.090 
Arterial Hypertension, n (%) 40 (39.6%) 7 (33.3%) 0.632 
Metabolic Syndrome, n (%) 37 (36.6%) 5 (45.5%) 0.858 
Co-morbidities, n (%) 
 
None 
Cardiovascular disease 
Kidney disease 
Thyroid disease 
Mental depression 
Biliary stones 
Bronchopathy 
Vasculitis 
Dermatologic disease 
 
 
64 (63.4%) 
8 (7.9%) 
3 (3%) 
6 (5.9%) 
4 (4%) 
4 (4%) 
3 (3%) 
2 (2%) 
7 (6.9%) 
 
 
14 (66.7%) 
1 (4.8%) 
2 (9.5%) 
0 (0%) 
2 (9.5%) 
0 (0%) 
0 (0%) 
2 (9.5%) 
0 (0%) 
0.267 
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Table 3. Baseline liver-related clinical, biochemical, virological and 
metabolic features of the patients. 
Abbreviations: IL28B, Interleukin 28B; GGT, Gamma-glutamyltranspeptidase; HCC, 
epatocellular carcinoma; HbA1c, Glycated haemoglobin; OHA, oral hypoglycemic 
agents. 
 Group 1 
(101 patients) 
Group 2 
(21 patients) 
p 
HCV-RNA (log10 IU/mL)* 6.50 (6.11 – 6.76) 6.71 (6.26 – 6.92) 0.391 
Genotype, n (%) 
 
1a 
1b 
2 
3 
4 
 
 
4 (4%) 
55 (54.5%) 
13 (12.9%) 
19 (18.8%) 
10 (9.9%) 
 
 
1 (5%) 
13 (65%) 
1 (5%) 
3 (15%) 
2 (10%) 
0.85 
IL28B, n (%) 
 
CC 
CT 
TT 
 
 
 
22 (22%) 
59 (58%) 
20 (10%) 
 
 
 
12 (57%) 
8 (38%) 
1 (5%) 
 
 
0.06 
Liver stiffness (kPa) * 24.31± 14.79 18.62    12.52 0.11 
Metavir, n (%) 
 
0-1 
2 
3 
4 
 
 
6 (5.9%) 
3 (3%) 
19 (18.8%) 
73 (72.3%) 
 
 
4 (19.1%) 
5(23.8%) 
2 (9.5%) 
10 (47.6%) 
 
0.024 
Cirrhosis, n (%) 
 
Child A 
Child B 
 
 
63 (86%) 
10  (14%) 
 
 
7 (70%) 
3 (30%) 
 
 
0.365 
Previous HCC, n (%) 6 (6%) 1 (5%) 1 
Oesophageal/gastric varices, n (%) 46 (45.5%) 6 (28.6%) 0.235 
 
Diet only 
Diet + OHA 
Diet + insulin 
Diet + OHA+ insulin 
 
 
36 (35.6%) 
19 (18.8%) 
38 (37.6%) 
8 (7.9%) 
 
 
7 (33.3%) 
8 (38.1%) 
4 (19%) 
2 (9.5%) 
 
0.081 
Retinopathy, n (%) 7 (6.9) 3 (14.3%) 0.374 
Nephropathy, n (%) 2 (2%) 0 (0%) 0.436 
Coronary artery disease, n (%) 2 (2%) 0 (0%) 1 
Peripheral artery disease, n (%) 5 (5%) 0 (0%) 0.586 
Neuropathy, n (%) 4 (4%) 0 (0%) 1 
* mean ± SD 
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Table 4. Anthropometric, biochemical and metabolic variations in 
sustained responders and relapsing/untreated patients.  
 Group 1 
(101 patient) 
Group 2 
(21 patients) 
Baseline End of study p Baseline End of study p 
AST (IU/mL) * 42.3 ± 37.6 28.2 ± 11.0 0.02 40.3 ± 38.4 42.2 ± 39.8 0.85 
ALT (IU/mL) * 81.2 ± 77.2 36.0 ± 12.0 <0.001 78.7 ± 67.3 82.2 ± 71.6 0.74 
GGT (IU/mL) * 87.8 ± 81.0 62.5 ± 73.2 0.02 65.2 ± 64.0 67.0 ± 68.1 0.43 
Bilirubin (mg/dL) § 1.0 (0.6 – 1.8) 0.8 (0.7 – 1.1) 0.12 0.9 (0.6 – 1.3) 1.0 (0.7 -  1.4) 0.52 
Albumin (g/L) § 42 (31 – 48) 44 (33 – 49) 0.09 43 (34 – 47) 42 (33 – 48) 0.78 
INR§ 1.3 (1.0 – 1.8) 1.0 (1.0 – 1.5) 0.08 1.2 (1.0 – 1.7) 1.3 (1.0 – 2.1) 0.33 
Leukocytes 
(x103/µL cells) § 
4.2 (2.2 – 7.8) 5.4 (3.3 – 8.2) 0.07 4.4(2.8 – 6.2) 4.1 (2.3 – 7.3) 0.64 
Platelets 
(x103/µL cells) § 
155 (62 – 287) 173 (52 – 274) 0.08 164 (73 – 245) 162 (68 – 274) 0.35 
Glucose (mg/dL) * 152.4 ± 56.4 134.3 ± 41.3 0.002 145.3 ± 30.2 140.0 ± 47.9 0.71 
HbA1c 
(mmol/mol) * 
52.2 ± 15.4 46.5 ± 16.2 <0.001 53.4 ± 9.5 55.3 ± 20.6 0.78 
HOMA-IR* 5.2 ± 2.5 3.1 ± 1.6 <0.001 4.9 ± 2.6 4.6 ± 2.3 0.29 
Body weight (kg) * 75.3 ± 13.7 77.9 ± 19.8 0.02 76.6 ± 19.3 76.9 ± 20.7 0.56 
* mean ± SD 
§ median (range) 
 
Abbreviations: AST, Aspartate transaminase; ALT, alanine transaminase; GGT, 
Gamma-glutamyltranspeptidase; INR, International Normalized Ratio; HbA1c, 
Glycated haemoglobin; HOMA-IR, Homeostasis Model Assessment – Insulin 
Resistance 
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Table 5.Results of the multivariable Cox regression analysis of the factors 
potentially associated with significant improvement of glycaemic control. 
 
 
OR C.I. p 
HCV RNA levels 0.999 0.999-1.000 0.154 
Liver stiffness 1.014 0.970-1.059 0.541 
GGT levels 1.002 0.996-1.009 0.496 
Albumine levels 0.713 0.224-2.275 0.568 
Platelets 0.999 0.999-1.000 0.256 
BMI 1.115 0.976-1.274 0.108 
SVR 49.75 2.197-112.67 0.014 
Insulin therapy 1.379 0.408-4.659 0.605 
Arterial hypertension 1.083 0.339-3.465 0.893 
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Figure 1 
